NVO

Novo Nordisk A/S

Fundamental data last updated:July 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NYSE

County of HQ

DK

Next Earnings Date

08/05/2026

Business Summary

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

 


Analyze NVO on TradingView

VALUATION

P/E

1.67

Market Cap ($M USD)

$203.30B

Forward P/E

1.58

PEG

0.31

PRICE TO SALES

3.97

PRICE TO BOOK

6.41

EV / EBITDA

7.76

5-Year Average P/E

Free Cash Flow Yield

2.38%

DCF Value

$96.28

Graham Number

$168.03

Price to FCF

41.94

EV to FCF

45.98

Earnings Yield

9.37%

FCF Yield

2.38%

DIVIDEND

Yield

3.99%

Annual Payout

$11.70

Payout Ratio

42.47%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$27.45

Next Year EPS Growth Estimate

$28.87

Next Year Revenue Growth Estimate

$38.05T

Return on Equity (ROE)

66.36%

FREE CASH FLOW

Operating Margin

45.30%

Debt-to-Equity

0.67

Piotroski F-Score

5

Altman Z-Score

4.11

Return on Invested Capital (ROIC)

44.45%

Current Ratio

0.79

Quick Ratio

0.56

Net Debt to EBITDA

0.68

Interest Coverage

29.15

Gross Profit margin

81.85%

FCF PER SHARE

$6.98

REVENUE PER SHARE

$73.79

Analyze NVO on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be significantly undervaluing Novo Nordisk A/S. With a DCF value nearly double the snapshot price, the stock appears to be trading at a discount. The Forward P/E ratio suggests a more attractive valuation compared to its current P/E, indicating potential growth. The Altman Z-score of 4.10 signals strong financial health, reducing bankruptcy risk. Meanwhile, an earnings yield of 9.55% highlights robust profitability, making this stock a compelling opportunity for value investors.

AI Exposure / Tech Reliance

In the biotechnology sector, Novo Nordisk is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The company's focus on healthcare innovation aligns with tech-driven efficiencies. This adaptability ensures resilience in a rapidly evolving industry landscape.

The Bull Case

For GARP investors, Novo Nordisk offers a compelling case with its impressive ROIC of 44.45%, showcasing exceptional capital efficiency. The company's FCF yield, though modest, is bolstered by a strong operating margin of 45.30%, reflecting solid pricing power. A Piotroski F-Score of 5 indicates decent financial strength, while the robust gross profit margin underscores its ability to generate cash effectively. These metrics paint a picture of a company with both growth potential and financial discipline.

The Bear Case

Despite its strengths, Novo Nordisk faces challenges with high valuation multiples, such as a Price/Book ratio of 6.29 and a Price/Sales ratio of 3.89, which may deter value investors. The current ratio of 0.79 and quick ratio of 0.56 suggest potential liquidity concerns. Additionally, the stock is trading close to its 52-week high, indicating possible technical overextension. These factors could pose risks to investors seeking immediate value.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$47.00

Institutional Ownership %

1-Year Beta

0.35

Insider Buying % (6 Mo)

Distance to 52-Week High

78.01%

Distance to 52-Week Low

23.23%

EARNINGS SURPRISE %

19.54%

50-DAY SMA

$40.95

200-DAY SMA

$48.99

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.